104 | A GLOBAL PHASE 1B STUDY OF JNJ‐90014496, A CD19/CD20 BI‐SPECIFIC CHIMERIC ANTIGEN RECEPTOR (CAR) T‐CELL THERAPY, IN RELAPSED/REFRACTORY (R/R) LARGE B‐CELL LYMPHOMA (LBCL)
Krina K. Patel(University of Vermont), Matthew Ku(St Vincent's Hospital Melbourne), Melissa Beelen(Janssen (United States)), J. Baird(City of Hope), Maeve O’Reilly(Royal London Hospital), Nosha Farhadfar(University of Florida Health), Luke Mountjoy(Colorado Blood Cancer Institute), Constantine S. Tam(The Alfred Hospital), Yasmina Serroukh(Erasmus MC), Kathleen Dorritie(University of Pittsburgh), Mahipal Suraneni(Johnson & Johnson (United States)), Youngil Koh(Seoul National University), M. Hutchings(University of Copenhagen), Leen Slaets(European Organisation for Research and Treatment of Cancer), Arnob Banerjee(Johnson & Johnson (United States)), Jacqueline Bussolari(Johnson & Johnson (United States)), Joanna Rhodes(Roswell Park Comprehensive Cancer Center), A. Abdulgawad(The Christie NHS Foundation Trust), Allison Barraclough(Fiona Stanley Hospital), Alfredo Perales‐Puchalt(The Wistar Institute), Daniel Morillo(Hospital Universitario Fundación Jiménez Díaz), Laura Magnano(Hospital Clínic de Barcelona), Woo Seob Kim(Samsung Medical Center), John Kuruvilla(Princess Margaret Cancer Centre), Margot Jak, Umar Farooq(Wake Forest University), Jacob Haaber Christensen(Odense University Hospital), Julie S. Larsen(Janssen (United States)), Amritha Ramakrishnan(United States Naval Medical Research Unit SOUTH), Matthew Schwede(Stanford University), James J. Wu(Glenn Research Center), Paul Shaughnessy(CHRISTUS Transplant Institute)
Cited by 0
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k